High metastatic tumor burden was evident in mice receiving anti-PD-L1 ICB alone, but significantly (P < 0.0001) reduced in mice receiving nAlb-diABZI and nearly eliminated in mice receiving AP-diABZI. This evidence concerns the gene CD274 and neoplasm.